Rational targeting Cdc42 restrains Th2 cell differentiation and prevents allergic airway inflammation
Summary Background Asthma is an allergic airway inflammation‐driven disease that affects more than 300 million people world‐wide. Targeted therapies for asthma are largely lacking. Although asthma symptoms can be prevented from worsening, asthma development cannot be prevented. Cdc42 GTPase has been...
Saved in:
Published in | Clinical and experimental allergy Vol. 49; no. 1; pp. 92 - 107 |
---|---|
Main Authors | , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Wiley Subscription Services, Inc
01.01.2019
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Summary
Background
Asthma is an allergic airway inflammation‐driven disease that affects more than 300 million people world‐wide. Targeted therapies for asthma are largely lacking. Although asthma symptoms can be prevented from worsening, asthma development cannot be prevented. Cdc42 GTPase has been shown to regulate actin cytoskeleton, cell proliferation and survival.
Objectives
To investigate the role and targeting of Cdc42 in Th2 cell differentiation and Th2‐mediated allergic airway inflammation.
Methods
Post‐thymic Cdc42‐deficient mice were generated by crossing Cdc42flox/flox mice with dLckicre transgenic mice in which Cre expression is driven by distal Lck promoter. Effects of post‐thymic Cdc42 deletion and pharmacological targeting Cdc42 on Th2 cell differentiation were evaluated in vitro under Th2‐polarized culture conditions. Effects of post‐thymic Cdc42 deletion and pharmacological targeting Cdc42 on allergic airway inflammation were evaluated in ovalbumin‐ and/or house dust mite‐induced mouse models of asthma.
Results
Post‐thymic deletion of Cdc42 led to reduced peripheral CD8+ T cells and attenuated Th2 cell differentiation, with no effect on closely related Th1, Th17 and induced regulatory T (iTreg) cells. Post‐thymic Cdc42 deficiency ameliorated allergic airway inflammation. The selective inhibition of Th2 cell differentiation by post‐thymic deletion of Cdc42 was recapitulated by pharmacological targeting of Cdc42 with CASIN, a Cdc42 activity‐specific chemical inhibitor. CASIN also alleviated allergic airway inflammation. CASIN‐treated Cdc42‐deficient mice showed comparable allergic airway inflammation to vehicle‐treated Cdc42‐deficient mice, indicative of negligible off‐target effect of CASIN. CASIN had no effect on established allergic airway inflammation.
Conclusion and Clinical Relevance
Cdc42 is required for Th2 cell differentiation and allergic airway inflammation, and rational targeting Cdc42 may serve as a preventive but not therapeutic approach for asthma control. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 AUTHOR CONTRIBUTIONS J. Q. Y. designed and performed research, analyzed data, and wrote the paper; K. W. K. performed research and analyzed data; Y.L. performed research and analyzed data; X. D. performed research; P.N. performed research; G.K.K.H. designed research, analyzed data, and contributed vital new reagents or analytical tools; J.K. performed research and analyzed data; B.R. performed research and analyzed data; L.Z. analyzed data; N.S. analyzed data; M.R. performed research; T.W. designed and performed research, analyzed data, and wrote the paper; M.E.R. designed research, contributed vital new reagents or analytical tools, and wrote the paper; Y. Z. designed research and contributed vital new reagents or analytical tools; F. G. designed research, analyzed data, contributed vital new reagents or analytical tools, and wrote the paper. |
ISSN: | 0954-7894 1365-2222 |
DOI: | 10.1111/cea.13293 |